Ülke: ABD
Dil: İngilizce
Kaynak: NLM (National Library of Medicine)
Diflorasone Diacetate (UNII: 7W2J09SCWX) (Diflorasone - UNII:T2DHJ9645W)
Emerald Therapeutics, LLC
TOPICAL
PRESCRIPTION DRUG
Diflorasone diacetate cream USP is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Diflorasone diacetate cream USP, 0.05% is available in a 60 g tube, NDC 72919-549-60. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Keep tightly closed.
Abbreviated New Drug Application
DIFLORASONE DIACETATE- DIFLORASONE DIACETATE CREAM EMERALD THERAPEUTICS, LLC ---------- DIFLORASONE DIACETATE CREAM USP, 0.05% RX ONLY FOR EXTERNAL USE ONLY - NOT FOR OPHTHALMIC USE. DESCRIPTION Diflorasone diacetate cream USP, 0.05% contains the active compound diflorasone diacetate, a synthetic corticosteroid for topical dermatological use. Chemically, diflorasone diacetate is 6α, 9α-difluoro-11β,17,21-trihydroxy-16- methylpregna-1,4-diene-3,20-dione 17,21 diacetate, with the empirical formula C H F O , a molecular weight of 494.5, and the following structural formula: Each gram of diflorasone diacetate cream USP, 0.05% contains 0.5 mg diflorasone diacetate in a cream base consisting of butylated hydroxytoluene, cetyl alcohol, citric acid, glyceryl stearate/PEG 100 stearate, isopropyl myristate, lanolin alcohol, mineral oil, monobasic sodium phosphate, polyoxyl 40 stearate, polysorbate 60, propylene glycol, purified water, sorbitan monostearate and vegetable oil. CLINICAL PHARMACOLOGY Like other topical corticosteroids, diflorasone diacetate has anti-inflammatory, anti- pruritic, and vasoconstrictive actions. The mechanism of the anti-inflammatory activity of the topical corticosteroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A inhibitory proteins collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent 26 32 2 7 2 mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A . PHARMACOKINETICS The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical co Belgenin tamamını okuyun